Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Crohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab.

Trial Profile

Prospective Study to Assess the Efficacy of Switching to Infliximab in Moderately to Severely Active Crohn's Disease Patients With Primary Non-response or Loss of Response to Adalimumab.

Recruiting
Phase of Trial: Phase IV

Latest Information Update: 27 Feb 2017

At a glance

  • Drugs Infliximab (Primary)
  • Indications Crohn's disease
  • Focus Therapeutic Use
  • Most Recent Events

    • 07 Jun 2017 Biomarkers information updated
    • 04 Dec 2014 Planned End Date changed from 1 Jul 2013 to 1 Jul 2015 as reported by ClinicalTrials.gov.
    • 18 Nov 2011 Additional trial identifier 2010-566 identified as reported by ClinicalTrials.gov.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top